TP53 and acute myeloid leukemia: Parthenolide was also shown to preferentially target AML progenitors (in vitro colony assay) and stem cell population in SCID mice xenograft model through the inhibition of NF-κB, proapoptotic activation of tumor suppressor p53, and increased reactive oxygen species (ROS) production [27].